https://missiontherapeutics.com/mission-appoints-dr-colin-goddard-to-its-board-of-directors/2015-07-01T15:45:03+01:00https://missiontherapeutics.com/prof-steve-jackson-to-give-sackler-lecture/2015-06-11T15:48:31+01:00https://missiontherapeutics.com/mission-therapeutics-presents-at-aacr-the-identification-of-novel-inhibitors-of-the-uchl1-oncogene/2015-04-24T15:52:11+01:00https://missiontherapeutics.com/mission-therapeutics-wins-new-life-science-innovation-award/2015-03-20T14:53:03+00:00https://missiontherapeutics.com/mission-appoints-paul-wallace-as-chief-business-officer/2015-03-16T14:57:10+00:00https://missiontherapeutics.com/mission-appoints-anker-lundemose-as-chief-executive-officer/2015-01-09T14:58:46+00:00https://missiontherapeutics.com/mission-therapeutics-appoints-michael-koslowski-as-chief-medical-officer/2015-09-01T10:00:25+01:00https://missiontherapeutics.com/mission-therapeutics-receives-funding-from-innovate-uk-for-dub-cancer-programme/2015-09-22T15:02:40+01:00https://missiontherapeutics.com/mission-therapeutics-appoints-david-luther-as-chief-financial-officer/2015-10-01T08:05:30+01:00https://missiontherapeutics.com/mission-therapeutics-raises-60-million/2016-02-02T07:18:47+00:00https://missiontherapeutics.com/mission-therapeutics-to-present-at-conferences-in-march-2016/2016-03-01T09:17:47+00:00https://missiontherapeutics.com/mission-therapeutics-appoints-dr-anne-phelan-as-senior-vice-president-head-of-discovery-research/2017-03-20T09:19:12+00:00https://missiontherapeutics.com/mission-therapeutics-nominated-as-biotech-and-money-2017-awards-double-finalist/2017-06-09T16:35:55+01:00https://missiontherapeutics.com/mission-therapeutics-to-present-at-conferences-in-march-april-2016/2016-03-31T09:27:17+01:00https://missiontherapeutics.com/mission-therapeutics-to-attend-and-present-at-conferences-in-may-2016/2016-05-04T10:44:30+01:00https://missiontherapeutics.com/mission-therapeutics-to-attend-and-present-at-conferences-in-june-and-july-2016/2016-06-15T12:52:08+01:00https://missiontherapeutics.com/mission-therapeutics-wins-one-to-watch-private-uk-life-science-company-of-the-year/2016-09-07T14:17:24+01:00https://missiontherapeutics.com/dr-michael-koslowski-listed-in-the-top-20-translational-researchers/2016-10-06T15:13:49+01:00https://missiontherapeutics.com/mission-therapeutics-to-attend-and-present-at-conferences-in-october-and-november-2016/2016-10-13T09:25:35+01:00https://missiontherapeutics.com/1858-2/2016-12-05T15:43:06+00:00https://missiontherapeutics.com/mission-therapeutics-and-university-of-oxford-awarded-research-grant-from-the-michael-j-fox-foundation/2017-04-11T09:11:55+01:00https://missiontherapeutics.com/mission-therapeutics-appoints-scientific-advisory-board/2017-07-19T15:55:53+01:00https://missiontherapeutics.com/mission-therapeutics-scientists-highlight-significance-of-deubiquitylating-enzymes-dubs-as-key-drug-targets/2017-09-29T13:44:26+01:00https://missiontherapeutics.com/mission-therapeutics-presenting-at-the-michael-j-fox-foundations-parkinsons-disease-therapeutics-conference/2017-10-30T13:03:22+00:00https://missiontherapeutics.com/mission-therapeutics-scientists-presenting-novel-parkinsons-usp30-target-and-inhibitor-data-at-the-society-for-neuroscience-2017-annual-meeting/2017-11-01T09:53:54+00:00https://missiontherapeutics.com/mission-therapeutics-highlights-positive-parkinsons-disease-usp30-target-and-inhibitor-data-at-the-society-for-neuroscience-2017-annual-meeting/2017-11-16T08:30:16+00:00https://missiontherapeutics.com/mission-therapeutics-strengthens-senior-management-team-with-appointment-of-dr-paul-thompson-vice-president-clinical-development/2018-03-01T09:11:56+00:00https://missiontherapeutics.com/mission-therapeutics-appoints-dr-bobby-soni-to-its-board-of-directors/2018-03-08T09:30:22+00:00https://missiontherapeutics.com/mission-therapeutics-strengthens-clinical-development-team-with-appointment-of-dr-judit-molnar-as-senior-director-translational-medicine/2018-09-04T08:47:00+01:00https://missiontherapeutics.com/mission-therapeutics-and-abbvie-sign-dubs-collaboration-in-alzheimers-and-parkinsons-disease/2018-11-15T08:02:38+00:00https://missiontherapeutics.com/dr-nick-edmunds-appointed-to-vp-head-of-dub-discovery/2018-12-03T09:02:07+00:00https://missiontherapeutics.com/mission-therapeutics-to-present-at-the-cowen-and-company-39th-annual-healthcare-conference/2019-03-06T16:33:56+00:00https://missiontherapeutics.com/dr-james-summers-appointed-to-mission-therapeutics-board-of-directors/2019-05-01T08:06:23+01:00https://missiontherapeutics.com/mission-therapeutics-collaboration-with-abbvie-nominated-for-scrip-best-partnership-alliance-award/2019-09-16T12:51:52+01:00https://missiontherapeutics.com/biomed-realty-announces-first-lettings-at-babraham-research-campus-in-cambridge/2019-10-22T11:20:00+01:00https://missiontherapeutics.com/mission-and-abbvies-collaboration-in-alzheimers-and-parkinsons-diseases-reaches-milestone/2019-12-03T10:30:17+00:00https://missiontherapeutics.com/mission-moves-to-new-babraham-campus-headquarters/2020-06-02T09:00:58+01:00https://missiontherapeutics.com/mission-raises-15m-and-expands-its-relationship-with-pfizer/2020-07-06T08:59:01+01:00https://missiontherapeutics.com/mission-and-imperial-college-london-report-potent-and-selective-probe-for-deubiquitylating-enzyme-uchl1/2020-07-07T08:57:05+01:00https://missiontherapeutics.com/key-appointments-strengthen-mission-therapeutics-senior-management-team/2020-08-04T09:56:31+01:00https://missiontherapeutics.com/mission-therapeutics-appoints-dr-suhail-nurbhai-as-chief-medical-officer/2020-11-02T08:00:15+00:00https://missiontherapeutics.com/mission-therapeutics-ceo-to-present-at-the-sachs-annual-european-life-sciences-ceo-forum/2021-03-09T09:51:47+00:00https://missiontherapeutics.com/mission-therapeutics-cso-to-present-at-the-targeted-protein-degradation-europe-summit/2021-03-15T14:58:21+00:00https://missiontherapeutics.com/mission-therapeutics-welcomes-co-founder-of-rosetta-capital-jonathan-hepple-to-its-board-of-directors/2021-03-24T08:59:03+00:00https://missiontherapeutics.com/mission-therapeutics-nominates-first-development-candidates-targeting-usp30/2021-03-25T11:06:10+00:00https://missiontherapeutics.com/mission-therapeutics-to-participate-in-upcoming-svb-leerink-biopharma-private-company-connect-event/2021-04-22T10:14:32+01:00https://missiontherapeutics.com/mission-therapeutics-to-present-at-the-mitochondria-targeted-drug-development-summit/2021-04-26T09:03:03+01:00https://missiontherapeutics.com/mission-therapeutics-to-attend-and-present-at-bioequity-europe-digital-2021/2021-05-14T09:00:19+01:00https://missiontherapeutics.com/mission-therapeutics-invited-to-present-at-ubs-innovation-series-the-next-wave-in-neurodegeneration/2021-06-02T09:00:05+01:00https://missiontherapeutics.com/mission-therapeutics-to-present-at-solebury-trout-venrock-and-oppenheimers-eu-summer-investor-tour/2021-07-13T11:59:12+01:00https://missiontherapeutics.com/mission-and-abbvie-collaboration-in-alzheimers-and-parkinsons-diseases-reaches-next-milestone/2021-08-09T09:00:10+01:00https://missiontherapeutics.com/mission-therapeutics-to-participate-in-the-solebury-trout-fall-private-company-showcase-2021/2021-10-11T09:18:21+01:00https://missiontherapeutics.com/mission-therapeutics-awarded-follow-on-therapeutic-pipeline-program-grant-from-the-michael-j-fox-foundation/2021-10-12T08:57:27+01:00https://missiontherapeutics.com/mission-therapeutics-to-participate-in-the-bmo-biopharma-spotlight-series-2022/2022-02-21T09:00:51+00:00https://missiontherapeutics.com/mission-therapeutics-to-participate-in-the-2022-babraham-research-campus-signalling-event/2022-03-07T12:03:47+00:00https://missiontherapeutics.com/mission-therapeutics-to-present-at-the-2nd-annual-target-protein-degradation-europe-summit/2022-03-15T15:47:03+00:00https://missiontherapeutics.com/mission-therapeutics-to-participate-in-bio-europe-spring-2022/2022-03-22T10:18:31+00:00https://missiontherapeutics.com/mission-therapeutics-to-participate-in-svb-leerink-biopharma-private-company-connect-event/2022-03-25T10:04:17+00:00https://missiontherapeutics.com/mission-therapeutics-authorised-to-initiate-first-clinical-trial-for-lead-dub-program-mtx652-in-kidney-disease/2022-03-31T11:12:28+01:00https://missiontherapeutics.com/5579-2/2022-10-11T14:51:47+01:00https://missiontherapeutics.com/mission-therapeutics-to-attend-the-michael-j-fox-foundations-14th-annual-parkinsons-disease-therapeutics-conference/2022-10-12T09:00:58+01:00https://missiontherapeutics.com/new-data-from-harvard-medical-school-highlights-usp30-reduction-as-a-potential-strategy-for-treatment-of-parkinsons-disease/2022-11-14T15:24:42+00:00https://missiontherapeutics.com/mission-therapeutics-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference/2023-01-03T13:27:26+00:00https://missiontherapeutics.com/mission-therapeutics-successfully-completes-first-clinical-assessment-for-lead-dub-program-mtx652/2023-01-05T08:39:52+00:00https://missiontherapeutics.com/mission-therapeutics-to-present-at-the-targeted-protein-degradation-europe-conference-2023/2023-03-06T11:33:31+00:00https://missiontherapeutics.com/mission-therapeutics-founder-to-receive-knighthood-in-birthday-honours-list/2023-06-23T11:34:21+01:00https://missiontherapeutics.com/mission-therapeutics-to-present-at-michael-j-fox-foundations-15th-annual-parkinsons-disease-therapeutics-conference/2023-10-10T11:49:13+01:00https://missiontherapeutics.com/mission-therapeutics-to-present-abstract-at-american-society-of-nephrology-asn-kidney-week-2023/2023-11-01T15:08:21+00:00https://missiontherapeutics.com/mission-therapeutics-announces-publication-in-nature-communications-outlining-potential-of-experimental-drug-mtx325-as-a-disease-modifying-therapy-for-parkinsons-disease/2023-11-10T17:58:27+00:00https://missiontherapeutics.com/mission-therapeutics-granted-mhra-clinical-trial-authorisation-cta-for-mtx325-for-the-treatment-of-parkinsons-disease/2023-12-05T08:47:07+00:00https://missiontherapeutics.com/mission-therapeutics-announces-us-fda-approval-to-initiate-phase-ii-clinical-trial-of-its-lead-asset-mtx652-in-acute-kidney-injury/2023-12-14T15:26:48+00:00https://missiontherapeutics.com/mission-therapeutics-raises-25-2-million-to-progress-clinical-candidates-in-the-area-of-mitophagy/2024-03-14T07:53:43+00:00https://missiontherapeutics.com/mission-therapeutics-commences-landmark-trial-of-mtx325-a-potential-disease-modifying-treatment-for-parkinsons-disease/2024-03-20T12:58:46+00:00https://missiontherapeutics.com/mission-therapeutics-awarded-5-2m-from-the-michael-j-fox-foundation-and-parkinsons-uk-to-advance-potential-disease-modifying-treatment-mtx325/2024-07-02T09:48:47+01:00https://missiontherapeutics.com/mission-therapeutics-announces-publication-in-nature-reviews-drug-discovery-of-article-highlighting-how-neurodegenerative-diseases-can-be-tackled-by-enhancing-mitophagy/2025-01-15T08:21:33+00:00https://missiontherapeutics.com/mission-therapeutics-raises-13-3-million-to-progress-first-in-class-parkinsons-disease-candidate-mtx325-through-clinical-trials/2025-10-15T08:58:12+01:00